Compare Linde PLC (LIN) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs McKesson Corporation — how do they compare? Linde PLC trades at $483.73 (market cap $222.05B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: Linde PLC is far larger — about 2× McKesson Corporation's market cap, and Linde PLC pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and McKesson Corporation for 74 Days on average.
| LIN | MCK | |
|---|---|---|
Market Cap | $222.05B | $108.46B |
Volume | 2,116,440 | 712,607 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $995.69 |
52-Week Low | $389.38 | $725.17 |
Typical Hold Time | 88 Days | 74 Days |
Enterprise Value | $245.17B | $115.00B |
Dividend Yield | 1.33% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $481.70, down 0.47% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $4.50 beating estimates of $4.49, and maintains healthy profitability with a 20.43% net income margin. Analyst sentiment remains overwhelmingly positive with 89.66% buy ratings and a $557.10 consensus price target representing 15.6% upside potential from current levels.
The outlook remains favorable given Linde's leadership in industrial gases and exposure to AI chip manufacturing growth, though valuation at 31.08 P/E requires continued execution. Key risks include margin pressure from higher capital expenditures and competitive dynamics in the electronics sector. The stock's technical setup suggests support near $479 with resistance at $485, providing clear levels for near-term price action.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
